Diabetes Mellitus, Graft Rejection, Transplantation
Conditions
Keywords
regenerative medicine, stem cells, immunomodulatory, induced pluripotent stem cells, gut physiology
Brief summary
This study aims to use tissue from deceased organ donors to investigate organ physiology, developmental biology, as well as the development of future regenerative cellular therapies. It will investigate function and immune response to stem cells as well as their generation from adult cells and generation of induced pluripotent stem cells (iPSCs).
Detailed description
The purpose of this study is to use tissue from deceased organ donors to address questions that are of importance for the development of regenerative cellular therapies for better understanding of organ physiology and developmental biology. This study aims to maximise the clinically available data as well as patient benefit that can be generated from donated tissue. It also aims to reduce number of consent forms given to patients by consolidating and coordinating a number of related investigations. The study aims are: * To examine function and the immune response to stem cells and their differentiated progeny as well as development of immunomodulatory approaches to prevent their rejection. * Generation of induced pluripotent stem cells (iPSCs) and their subsequent differentiation into functional cells as potential therapies. * Generation of differentiated cells from native adult stem cells as cellular therapies. * Investigation of organ physiology.
Interventions
OTHERRemoval of tissue post-mortem
Sponsors
University of Cambridge
Cambridge Stem Cell Institute, Cambridge
Anne McLarent Laboratory of Regenerative Medicine, Cambridge
The Gurdon Institute, Cambridge
Sanger Institure, Cambridge
Institute of Metabolic Science, Cambridge
MRC Mitochondrial Biology Unit, Cambridge
Cambridge University Hospitals NHS Foundation Trust
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 92 Years
Healthy volunteers
Yes
Inclusion criteria
* All deceased organ donors with informed consent from the donor family
Exclusion criteria
* Donors aged \<16
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of donors from which induced Pluripotent Stem Cells were generated | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Number of stem cell lines for which the immune response was characterised | 5 years |
| Number of immunomodulatory therapies characterised | 5 years |
| Levels of baseline and stimulated gut hormones detected | 5 years |
Countries
United Kingdom
Contacts
Primary ContactKourosh Saeb-Parsy, PhD, FRCS
Backup ContactNikitas Georgakopoulos, BSc
Outcome results
None listed